93.07
Lemaitre Vascular Inc stock is traded at $93.07, with a volume of 12,388.
It is up +1.52% in the last 24 hours and down -4.10% over the past month.
LeMaitre Vascular Inc is a provider of medical devices and human tissue cryopreservation services mainly used in the treatment of peripheral vascular disease, end-stage renal disease, and cardiovascular disease. The company develops, manufactures, and markets vascular devices to address the needs of vascular surgeons and, to a lesser extent, other specialties such as cardiac surgeons, general surgeons, and neurosurgeons. Its diversified portfolio consists of branded products used in arteries and veins that are well known to vascular surgeons. It operates across the Americas, Europe, the Middle East and Africa, and Asia Pacific, with the majority of its revenue generated from the Americas.
See More
Previous Close:
$91.92
Open:
$92.98
24h Volume:
12,388
Relative Volume:
0.05
Market Cap:
$2.12B
Revenue:
$256.28M
Net Income/Loss:
$62.40M
P/E Ratio:
34.29
EPS:
2.7139
Net Cash Flow:
$79.12M
1W Performance:
-3.39%
1M Performance:
-4.10%
6M Performance:
+11.88%
1Y Performance:
+13.67%
Lemaitre Vascular Inc Stock (LMAT) Company Profile
Name
Lemaitre Vascular Inc
Sector
Industry
Phone
781-221-2266
Address
63 SECOND AVENUE, BURLINGTON, MA
Compare LMAT vs ISRG, BDX, ALC, MDLN, RMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
LMAT
Lemaitre Vascular Inc
|
92.98 | 2.10B | 256.28M | 62.40M | 79.12M | 2.7139 |
|
ISRG
Intuitive Surgical Inc
|
417.50 | 147.53B | 10.58B | 3.00B | 2.83B | 8.2437 |
|
BDX
Becton Dickinson Co
|
144.86 | 40.10B | 21.37B | 1.41B | 3.07B | 3.9437 |
|
ALC
Alcon Inc
|
66.09 | 32.33B | 10.63B | 819.00M | 1.59B | 1.6577 |
|
MDLN
Medline Inc
|
36.03 | 31.57B | 29.14B | 1.07B | 1.05B | 1.1956 |
|
RMD
Resmed Inc
|
192.58 | 27.96B | 5.54B | 1.52B | 1.74B | 10.37 |
Lemaitre Vascular Inc Stock (LMAT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-06-25 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Feb-28-25 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Feb-28-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Feb-13-25 | Initiated | Wells Fargo | Equal Weight |
| Oct-15-24 | Initiated | Cantor Fitzgerald | Neutral |
| Aug-02-24 | Resumed | Lake Street | Buy |
| May-31-24 | Resumed | ROTH MKM | Buy |
| Apr-26-24 | Upgrade | Stifel | Hold → Buy |
| Feb-06-24 | Resumed | KeyBanc Capital Markets | Sector Weight |
| Oct-23-23 | Initiated | JMP Securities | Mkt Outperform |
| Sep-06-23 | Initiated | Oppenheimer | Outperform |
| Aug-03-23 | Downgrade | Jefferies | Buy → Hold |
| May-03-23 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Oct-28-22 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Sep-16-21 | Initiated | Jefferies | Buy |
| Feb-12-21 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Mar-16-20 | Upgrade | Sidoti | Neutral → Buy |
| Oct-24-19 | Downgrade | First Analysis Sec | Strong Buy → Outperform |
| Oct-24-19 | Upgrade | Lake Street | Hold → Buy |
| Oct-14-19 | Upgrade | First Analysis Sec | Outperform → Strong Buy |
| Jul-25-19 | Reiterated | Barrington Research | Outperform |
| Jul-25-19 | Upgrade | First Analysis Sec | Neutral → Outperform |
| Oct-08-18 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Oct-08-18 | Upgrade | ROTH Capital | Neutral → Buy |
| Jun-08-18 | Resumed | ROTH Capital | Buy |
| Apr-26-18 | Downgrade | Stifel | Buy → Hold |
| Apr-26-18 | Upgrade | The Benchmark Company | Hold → Buy |
| Oct-27-17 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
| Oct-27-17 | Downgrade | The Benchmark Company | Buy → Hold |
| Jul-10-17 | Downgrade | Canaccord Genuity | Buy → Hold |
| Jul-10-17 | Downgrade | The Benchmark Company | Buy → Hold |
| Mar-21-17 | Initiated | First Analysis Sec | Overweight |
| Feb-22-17 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Sep-22-16 | Downgrade | Sidoti | Buy → Neutral |
| Jul-28-16 | Reiterated | Barrington Research | Outperform |
| Feb-25-16 | Reiterated | Barrington Research | Outperform |
View All
Lemaitre Vascular Inc Stock (LMAT) Latest News
Kennedy Capital Management LLC Has $20.11 Million Stock Position in LeMaitre Vascular, Inc. $LMAT - MarketBeat
LeMaitre Vascular Shareholders Back Directors, Pay and Auditor - TipRanks
LeMaitre Vascular, Inc. (NASDAQ:LMAT) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
LeMaitre Vascular declares $0.25 dividend - MSN
LeMaitre Vascular (NASDAQ:LMAT) Shares Cross Above 200 Day Moving AverageTime to Sell? - MarketBeat
LMAT Q1 2026 Earnings: EPS Slightly Beats Estimates, Shares RiseEarnings Deceleration Risk - newsline.com
LeMaitre Vascular Inc. (LMAT) Q1 2026 Earnings: EPS Slightly Beats Estimates Amid Modest Stock Uptick - newsline.com
Jefferies recaps meetings with Healthcare Services companies - Investing.com
LMAT Q1 2026 Earnings: EPS Beats Estimates by 0.86%, Shares Inch HigherAnnual Report - newsline.com
LeMaitre Vascular (NASDAQ: LMAT) director gets dividend equivalent awards - Stock Titan
LeMaitre Vascular (LMAT) director receives new dividend equivalent rights grants - Stock Titan
LeMaitre (NASDAQ: LMAT) director gets dividend equivalent right awards - Stock Titan
[Form 4] LEMAITRE VASCULAR INC Insider Trading Activity - Stock Titan
LeMaitre Vascular (LMAT) director receives dividend equivalent rights awards - Stock Titan
LeMaitre Vascular (NASDAQ: LMAT) CFO receives new dividend rights awards - Stock Titan
LeMaitre Vascular (LMAT) director receives dividend equivalent right grants - Stock Titan
LeMaitre Vascular (LMAT) awards dividend equivalent rights to executive - Stock Titan
LeMaitre Vascular (NASDAQ: LMAT) CEO gifts 11,974 shares, receives dividend rights - Stock Titan
Price-Driven Insight from (LMAT) for Rule-Based Strategy - Stock Traders Daily
LeMaitre Vascular (LMAT) holders approve directors, say-on-pay and 2026 auditor - Stock Titan
LeMaitre Vascular (LMAT) Gains Ground as Stock Approaches Key ResistanceUndervalued Stocks - newsline.com
LMAT Maintained by Barrington Research -- Price Target Steady at $120 - GuruFocus
LeMaitre Vascular (NASDAQ:LMAT) Receives Outperform Rating from Barrington Research - MarketBeat
Q3 2025 LeMaitre Vascular Inc Earnings Call Transcript - GuruFocus
LMAT Q1 2026 Earnings: Modest EPS Beat Amid Steady PerformanceDiluted EPS Report - newsline.com
How The LeMaitre Vascular (LMAT) Story Is Shifting As Analysts Lift Fair Value Targets - Yahoo Finance
LMAT Q1 2026 Earnings: EPS Beats Estimates by Narrow Margin, Stock Declines SlightlyBook Value Growth - newsline.com
AlphaQuest LLC Grows Position in LeMaitre Vascular, Inc. $LMAT - MarketBeat
LeMaitre Vascular Inc. (LMAT) Holds Steady Near $98 as Traders Await CatalystTrend Continuation Trade - The Legal Advocate
LeMaitre (LMAT) is an Incredible Growth Stock: 3 Reasons Why - Yahoo Finance
(LMAT) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Thrivent Financial for Lutherans Grows Stock Holdings in LeMaitre Vascular, Inc. $LMAT - MarketBeat
Winners And Losers Of Q1: LeMaitre (NASDAQ:LMAT) Vs The Rest Of The Surgical Equipment & ConsumablesSpecialty Stocks - Yahoo Finance
LeMaitre Vascular to join two major healthcare investor conferences in June - Pluang
LeMaitre to Participate at Upcoming Investor Conferences in June - The Manila Times
LeMaitre schedules June talks at Jefferies and Goldman healthcare events - Stock Titan
GSA Capital Partners LLP Has $1.72 Million Position in LeMaitre Vascular, Inc. $LMAT - MarketBeat
LeMaitre Vascular (LMAT) Unchanged at $101.43 — Range-Bound Trading 2026-05-20Wedge Breakout - The Legal Advocate
LeMaitre Vascular (LMAT) Q1 2026 Results Top Views on Strong RevenueEarnings Expansion Phase - newsline.com
Three Healthcare Stocks Facing Potential Headwinds in 2026 - IndexBox
LeMaitre Vascular, Inc. (NASDAQ:LMAT) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
A Quick Look at Today's Ratings for LeMaitre Vascular(LMAT.US), With a Forecast Between $105 to $124 - Moomoo
Wakefield Asset Management LLLP Buys New Position in LeMaitre Vascular, Inc. $LMAT - MarketBeat
5 Insightful Analyst Questions From LeMaitre’s Q1 Earnings Call - Yahoo Finance
LeMaitre Vascular stock (US52567J1079): Q1 beat and raised 2026 guidance - AD HOC NEWS
[SCHEDULE 13G/A] LEMAITRE VASCULAR INC Amended Passive Investment Disclosure - Stock Titan
LeMaitre Vascular Senior Vice President of Operations Trent Kamke Sells 44% Of Holding - Moomoo
(LMAT) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Why LeMaitre Vascular (LMAT) Is Down 10.9% After Raising 2026 Guidance And Boosting Dividends - simplywall.st
Barrington Maintains LeMaitre Vascular(LMAT.US) With Buy Rating, Raises Target Price to $120 - 富途牛牛
Down 17.2% in 4 Weeks, Here's Why LeMaitre (LMAT) Looks Ripe for a Turnaround - Yahoo Finance
Lemaitre Vascular Inc Stock (LMAT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):